Gilbert White

Alternative Text

Gilbert C. White, II is EVP and Chief Science Officer Emeritus of Versiti and Director Emeritus of the Versiti Blood Research Institute, Richard H. and Sara E. Aster Chair of Medical Research, Associate Dean for Research Emeritus at Medical College of Wisconsin, and Professor of Medicine, Pharmacology and Toxicology, and Biochemistry Emeritus at Medical College of Wisconsin. He was previously John C. Parker Professor of Medicine and Pharmacology at his undergraduate and medical alma mater, the University of North Carolina, where he served as Director of the Center for Thrombosis and Hemostasis, and Director of the Harold R. Roberts Hemophilia Center. He was Associate/Co-Director of MSTP programs at both UNC and MCW.

Throughout his career as a physician-scientist, Dr White was Involved in both bench and clinical research. At the bench, his research was aimed at understanding signal transduction mechanisms in blood platelets with a goal of developing increasingly effective methods of controlling platelets in the development of vascular diseases. In the clinic, he led the first clinical trials of recombinant products in hemophilia, the first in vivo gene therapy trial in hemophilia, the initial drug trials of AZT for AIDS in hemophilia and interferon and ribavirin for hepatitis C in hemophilia, and studies to understand the genetic basis of inhibitors in hemophilia.

Continuously funded by the NIH for over forty years, Dr. White is presently co-PI on the Clinical and Translational Science Institute (CTSI) of Southeastern Wisconsin. He served on numerous NIH review and other committees and boards during his career, including the NHLBI Council and NIH Council of Councils. From 1999-2009, he was Executive Director of the International Society on Thrombosis and Hemostasis. He is co-Editor of the leading textbook in his field, Hemostasis and Thrombosis. Basic Principles and Clinical Practice. He currently serves on a few boards, including Pathway to Cures (P2C), a venture-philanthropy organization under the National Bleeding Disorders Foundation.